Yong Je Shin

This inventor holds 6 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Sk Biopharmaceuticals Co., Ltd.. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yong Je Shin. Retrieved from https://idiyas.com/inventor/yong-je-shin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 6)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 14.2

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Gyeonggi-do, KR (2023)
Daejeon, KR (2017 - 2024)

Company Filing History:

6 out of 109

Sk Biopharmaceuticals Co., Ltd.

patents

Years Active: 2017-2025

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12331035 - Bicyclic compound and use thereof (2025-06-17),

2. 12037338 - Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same (2024-07-16),

3. 11725001 - Bicyclic compound and use thereof (2023-08-15),

4. 11046702 - Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same (2021-06-29),

5. 10100057 - Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same (2018-10-16),

6. 9745310 - Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same (2017-08-29),

Title: Yong Je Shin: Innovator in Pharmaceutical Compounds

Introduction

Yong Je Shin is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific biological pathways. With a total of 6 patents to his name, his work has the potential to impact the treatment of various diseases.

Latest Patents

One of his latest patents is focused on a bicyclic compound and its use as a PRMT5 inhibitor. This invention relates to a 6-6 bicyclic ring-containing compound derivative, which can be effectively utilized in the prevention or treatment of diseases caused by PRMT5. Another notable patent involves an imidazopyrimidine and imidazotriazine derivative, along with a pharmaceutical composition comprising the same. This compound acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), making it useful in addressing disorders mediated by glutamate dysfunction.

Career Highlights

Yong Je Shin is currently associated with SK Biopharmaceuticals Co., Ltd., where he continues to innovate and develop new pharmaceutical solutions. His expertise in medicinal chemistry and compound development has positioned him as a key player in the industry.

Collaborations

He has collaborated with notable colleagues, including Chun Eung Park and Young Koo Jang, to advance research and development in the pharmaceutical sector.

Conclusion

Yong Je Shin's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving healthcare solutions. His work continues to pave the way for advancements in the treatment of various diseases.

Profile summary based on public USPTO records.